LTR Pharma appoints Nick Bell as Strategic Adviser
LTR Pharma Limited (ASX:LTP) has appointed Australian entrepreneur, investor and digital-growth specialist Nick Bell as Strategic Adviser to support the commercial growth of the Company’s broader men’s-health franchise. The appointment was announced on 4 November 2026.
Bell is known for building and scaling businesses internationally, and for his role as an investor on Shark Tank Australia. The appointment strengthens LTR Pharma’s capabilities across digital health, telehealth, strategic partnerships and commercial growth as its men’s-health portfolio expands.
When big ASX news breaks, our subscribers know first
What Nick Bell will do for LTR Pharma
As Strategic Adviser, Bell will work closely with LTR Pharma’s leadership team to identify and develop commercial opportunities across the Company’s expanding men’s-health portfolio.
Initial focus areas
His initial focus will include:
- Facilitating strategic introductions to telehealth platforms, clinic networks and commercial partners.
- Advising on digital-health and patient-engagement strategies.
- Supporting the evaluation of scalable and compliant commercial and patient-access pathways for SPONTAN® and KYZATREX® in Australia.
Management perspective
Executive Chairman Lee Rodne said the appointment fits the Company’s expansion plans in men’s health.
Lee Rodne, Executive Chairman
“As we expand our men’s-health portfolio, Nick will help us identify strategic partnerships, strengthen our digital-health strategy and evaluate compliant opportunities to connect eligible patients with appropriately qualified healthcare providers and treatment pathways.”
Bell pointed to the role of technology in the sector.
Nick Bell
“Men’s health is an area where digital innovation has the potential to significantly improve how patients connect with healthcare providers and access appropriate treatment.”
Who is Nick Bell?
Bell is described as having extensive experience building and scaling businesses across international markets. His background includes:
- Founding WME, which was acquired by Melbourne IT in 2017.
- Building a portfolio of businesses spanning digital marketing, technology, healthcare and consumer services, including First Page.
- Holding commercial interests across digital health, telehealth, medical imaging and longevity.
The Company said these interests provide valuable industry experience and strategic relationships relevant to LTR Pharma’s growth ambitions.
Why telehealth and digital pathways matter for men’s health
Telehealth platforms and clinic networks are channels through which patients can connect with qualified healthcare providers and, where appropriate, treatment. Digital tools can also support how patients engage with their care.
A live precedent already exists in the United States, where first ROXUS prescriptions are being fulfilled through the Mavrox telehealth platform and a licensed compounding pharmacy.
LTR Pharma is a commercial-stage pharmaceutical company. Its lead products, SPONTAN® and ROXUS®, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less, and KYZATREX® forms part of its men’s-health portfolio.
For investors, the relevance lies in the evaluation under way. Bell is expected to support the assessment of scalable and compliant commercial and patient-access pathways for SPONTAN® and KYZATREX® in Australia, which is an evaluation rather than an outcome.
| Focus area | Investor relevance |
|---|---|
| Telehealth platforms and clinic networks | Strategic introductions to potential commercial partners |
| Digital-health and patient-engagement strategy | Advice on how patients connect with providers |
| Patient-access pathways in Australia | Evaluation of scalable and compliant options for SPONTAN® and KYZATREX® |
LTR Pharma at a glance
- Commercial-stage pharmaceutical company with a proprietary intranasal technology platform.
- Has successfully commercialised its rapid-acting treatment technology in Australia.
- Expanding access whilst advancing regulatory pathways in the US and other key markets.
- Advancing OROFLOW®, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD), a group of conditions affecting swallowing function.
The OROFLOW ethics approval cleared a pilot study led by Dr Peter Wu of St George Hospital, which begins with healthy volunteers before moving to patients with achalasia and related disorders.
The appointment adds digital and commercial experience as LTR Pharma’s men’s-health portfolio expands.
Get Healthcare News Before the Market Moves
Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with in-depth analysis and the full announcement. Click the “Free Alerts” button at Big News Blast to get real-time alerts the moment market-moving healthcare news breaks.